Cardiac biomarkers are measurable substances found in blood that help clinicians assess heart function and detect cardiac-related events quickly and accurately. These indicators play a vital role in identifying conditions such as heart attacks, heart failure, and other forms of cardiac stress. By providing early and reliable signals, cardiac biomarkers support faster decision-making, timely treatment, and improved patient outcomes. Their importance continues to grow as healthcare systems emphasize rapid diagnosis and preventive care.

In 2024, the Cardiac Biomarkers Market was valued at USD 19.2 billion, reflecting widespread adoption of biomarker-based testing in clinical practice. This value is expected to increase to USD 21.51 billion in 2025, driven by rising demand for fast and precise diagnostic tools. Looking further ahead, long-term projections indicate substantial expansion, with the value forecast to reach USD 66.93 billion by 2035, supported by a strong 12.02% CAGR from 2024 to 2035. These figures underscore the growing reliance on advanced diagnostic solutions for cardiac care.

One of the key factors behind this growth is the increasing need for rapid testing. Cardiac events often require immediate attention, and biomarker tests help confirm or rule out conditions within a short timeframe. Improvements in sensitivity and specificity are enabling earlier detection, even at low biomarker concentrations. This enhances clinical confidence and reduces delays in treatment, which can be critical in emergency situations.